secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001650664-24-000094
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q2 2024 net loss $67.6M ($0.82/share), cash $318.3M, on track for clinical data by year-end
--------------------------------------------------------------------------------

- Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.
- Cash and equivalents $318.3M as of June 30, 2024 (down from $376.8M Q1); runway into 2026.
- R&D expenses $54.2M, up $24.4M driven by reni-cel program and in vivo research.
- On track to present additional clinical data from RUBY (SCD) and EdiTHAL (TDT) trials by year-end 2024.
- Completed enrollment of adult cohorts for both RUBY and EdiTHAL; adolescent cohort enrolled for RUBY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/0001650664-24-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/edit-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer